A Phase I/II trial of Cetuximab, Carboplatin and Radiotherapy for patients with locally advanced Head and Neck Squamous Cell Carcinoma.
The purpose of this study is to assess the safety and feasibility of combining radiotherapy and carboplatin (a chemotherapy drug) with a new drug called cetuximab in patients with locally advanced head and neck cancer
Primary Sponsor
Trans-Tasman Radiation Oncology Group (TROG)
Final Accrual
60
Trial Chairperson
Assoc Prof June Corry, Peter MacCallum Cancer Centre, VIC
Prof Danny Rischin, Peter MacCallum Cancer Centre, VIC
Clinical Trial Registration
Related Post
13 November, 2024
Trek4TROG team rise to Blue Mountains challenge
November 2024: Congratulations to the Trek4TROG team for successfully
24 October, 2024
Promising new results from RAIDER trial published
24 October 2024: Newly published findings from the TROG
